Treatment of HIV infection with the CCR5 antagonist maraviroc

Bibliography

• Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO). 2009. 09 AIDS epidemic update. Available from: http://www unaids org/en/KnowledgeCentre/HIVData/EpiUpdate/EpiUpdArchive/2009/default asp, 2010. [Last accessed 11 January 2010]
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 1 December 2009;1-161. Available from: http://www aidsinfo nih gov/ContentFiles/AdultandAdolescentGL pdf,9 A.D. [Last accessed 18 January 2010]
   Google Scholar
• European AIDS Clinical Society (EACS). Guidelines: Clinical management and treatment of HIV infected adults in Europe. Version 5. November 2009. Available from: http://www europeanaidsclinicalsociety org/guidelines asp, 2009. [Last accessed 18 January 2010]
   Google Scholar
• Sax PE. FDA approval: maraviroc. AIDS Clin Care 2007;19:75
   PubMedGoogle Scholar
• Briz V, Poveda E, Soriano V. HIV entry inhibitors: mechanisms of action and resistance pathways. J Antimicrob Chemother 2006;57:619-27
   PubMed Web of Science ®Google Scholar
• Este JA, Telenti A. HIV entry inhibitors. Lancet 2007;370:81-8
   PubMed Web of Science ®Google Scholar
• Chan SY, Speck RF, Power C, V3 recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1. J Virol 1999;73:2350-8
   PubMed Web of Science ®Google Scholar
• Huang W, Toma J, Fransen S, Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein. J Virol 2008;82:5584-93
   PubMed Web of Science ®Google Scholar
• Pastore C, Nedellec R, Ramos A, Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J Virol 2006;80:750-8
   PubMed Web of Science ®Google Scholar
• Dean M, Carrington M, Winkler C, Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996;273:1856-62
   PubMed Web of Science ®Google Scholar
• Eugen-Olsen J, Iversen AK, Garred P, Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS 1997;11:305-10
   PubMed Web of Science ®Google Scholar
• Liu R, Paxton WA, Choe S, Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-77
   PubMed Web of Science ®Google Scholar
• Walli R, Reinhart B, Luckow B, HIV-1-infected long-term slow progressors heterozygous for delta32-CCR5 show significantly lower plasma viral load than wild-type slow progressors. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:229-33
   PubMedGoogle Scholar
• Soriano V, Geretti AM, Perno CF, Optimal use of maraviroc in clinical practice. AIDS 2008;22:2231-40
   PubMed Web of Science ®Google Scholar
• Whitcomb JM, Huang W, Fransen S, Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007;51:566-75
   PubMed Web of Science ®Google Scholar
• Saag M, Heera J, Goodrich J, Reanalysis of the MERIT study with the enhanced TrofileTM assay (MERIT-ES) [abstract H-1232a]. Abstracts of the Forty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America Forty-sixth Annual Meeting; 28 October 2008; Washington, DC, USA
   Google Scholar
• Trinh L, Han D, Huang W, Technical validation of an enhanced sensitivity Trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5. Anitivir Ther 2008;3(Suppl 3):A128
   Google Scholar
• Cooper DA, Heera J, Goodrich J, Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010;201(6):803-13
   Google Scholar
• Poveda E, Briz V, Quinones-Mateu M, Soriano V. HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS 2006;20:1359-67
   PubMed Web of Science ®Google Scholar
• Verhofstede C, Reynes J, Poveda E, Correlation between population based-sequencing and viral tropism determination on PBMC DNA and plasma RNA in comparison with phenotypic methods. Abstracts of the Seventh European HIV Drug Resistance Workshop; 25-27 March 2009; Stockholm, Sweden
   Google Scholar
• Dorr P, Westby M, Dobbs S, Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005;49:4721-32
   PubMed Web of Science ®Google Scholar
• Abel S, Russell D, Whitlock LA, Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Br J Clin Pharmacol 2008;65(Suppl 1):60-7
   PubMedGoogle Scholar
• Abel S, van der Ryst E, Rosario MC, Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. Br J Clin Pharmacol 2008;65(Suppl 1):5-18
   PubMedGoogle Scholar
• Walker DK, Abel S, Comby P, Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos 2005;33:587-95
   PubMed Web of Science ®Google Scholar
• Chan PL, Weatherley B, McFadyen L. A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects. Br J Clin Pharmacol 2008;65(Suppl 1):76-85
   PubMedGoogle Scholar
• Fatkenheuer G, Pozniak AL, Johnson MA, Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005;11:1170-2
   PubMed Web of Science ®Google Scholar
• Abel S, Russell D, Taylor-Worth RJ, Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008;65(Suppl 1):27-37
   PubMedGoogle Scholar
• Abel S, Jenkins TM, Whitlock LA, Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008;65(Suppl 1):38-46
   PubMedGoogle Scholar
• Pozniak AL, Boffito M, Russell D, A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects. Br J Clin Pharmacol 2008;65(Suppl 1):54-9
   PubMedGoogle Scholar
• Abel S, Russell D, Whitlock LA, The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008;65(Suppl 1):47-53
   PubMedGoogle Scholar
• Heera J, Ive P, Botes M, The MERIT study of maraviroc in anti-retroviral-naive patients with R5 HIV-1: 96-week results [abstract TUAB103]. Abstracts of the Fifth International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention; 19-22 July 2009; Cape Town, South Africa
   Google Scholar
• Heera J, Saag M, Iversen AK, Virological correlates associated with treatment failure at week 48 in the Phase 3 study of maraviroc in treatment-naive patients [abstract 40LB]. Abstracts of the Fiftheenth Conference on Retroviruses and Opportunistics infections; 3-6 February 2008; Boston, MA, USA
   Google Scholar
• Gulick RM, Lalezari J, Goodrich J, Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429-41
   PubMed Web of Science ®Google Scholar
• Fatkenheuer G, Nelson M, Lazzarin A, Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008;359:1442-55
   PubMed Web of Science ®Google Scholar
• Dolin R. A new class of anti-HIV therapy and new challenges. N Engl J Med 2008;359:1509-11
   PubMed Web of Science ®Google Scholar
• Asmuth DM, Goodrich J, Cooper DA, CD4+ T-Cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 2009
   Google Scholar
• Saag M, Goodrich J, Fatkenheuer G, A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis 2009;199:1638-47
   PubMed Web of Science ®Google Scholar
• Saag M, Prudence I, Heera J, A multicentre, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive patients infected with R5 HIV 1:week 48 results of the MERIT study [abstract WESS 104]. Abstracts of the Fourth International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention; 22-25 July 2007; Sydney, Australia
   Google Scholar
• Lazzarin A, Di Perri G, Sierra-Madero JG, Fasted lipid changes after administration of maraviroc or efavirenz, both with zidovudine and lamivudine, to treatment-naive HIV-infected patients: 96-week results from MERIT. Abstracts of the Fortyninth Interscience Conference on Antimicrobial Agents and Chemotherapy; 12-14 September 2009; San Fransisco, CA, USA
   Google Scholar
• DeJesus E, Walmsley S, Cohen C, Fasted lipid changes after administration of maraviroc or efavirenz in combination with zidovudine and lamivudine for 48 weeks to treatment-naive HIV-infected patients. Abstracts of the Fiftheenth Conference on Retroviruses and Opportunistics infections; 3-6 February 2008; Boston, MA, USA
   Google Scholar
• Nichols WG, Steel HM, Bonny T, Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother 2008;52:858-65
   PubMed Web of Science ®Google Scholar
• Abel S, Davis JD, Ridgway CE, Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment. Antivir Ther 2009;14:831-7
   PubMed Web of Science ®Google Scholar
• Thio CL, Astemborski J, Bashirova A, Genetic protection against hepatitis B virus conferred by CCR5Delta32: evidence that CCR5 contributes to viral persistence. J Virol 2007;81:441-5
   PubMed Web of Science ®Google Scholar
• Gulick RM, Su Z, Flexner C, Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007;196:304-12
   PubMed Web of Science ®Google Scholar
• Glass WG, McDermott DH, Lim JK, CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006;203:35-40
   PubMed Web of Science ®Google Scholar
• Armand-Ugon M, Moncunill G, Gonzalez E, Different selection patterns of resistance and cross-resistance to HIV-1 agents targeting CCR5. J Antimicrob Chemother 2010;65(3):417-24
   Google Scholar
• Available from: http://www accessdata fda gov/scripts/cder/drugsatfda/index cfm?fuseaction=Search Label_ApprovalHistory#apphist Selzentry, 2009. [Last accessed 20 November 2009]
   Google Scholar
• Verhofstede C, Vandekerckhove L, Eygen VV, CXCR4-using HIV type 1 variants are more commonly found in peripheral blood mononuclear cell DNA than in plasma RNA. J Acquir Immune Defic Syndr 2009;50:126-36
   PubMed Web of Science ®Google Scholar
• Abrams D, Levy Y, Losso MH, Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009;361:1548-59
   PubMed Web of Science ®Google Scholar
• Poveda E, Rodes B, Labernardiere JL, Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. J Med Virol 2004;74:21-8
   PubMed Web of Science ®Google Scholar
• Westby M, Lewis M, Whitcomb J, Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006;80:4909-20
   PubMed Web of Science ®Google Scholar
• Stepanyuk O, Chiang TS, Dever LL, Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery. AIDS 2009;23:1911-3
   PubMed Web of Science ®Google Scholar
• Pope M, Haase AT. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med 2003;9:847-52
   PubMed Web of Science ®Google Scholar
• Dumond JB, Patterson KB, Pecha AL, Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr 2009;51:546-53
   PubMed Web of Science ®Google Scholar